Search Results - "Pattison, David A."

Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma by Kong, Grace, Grozinsky-Glasberg, Simona, Hofman, Michael S, Callahan, Jason, Meirovitz, Amichay, Maimon, Ofra, Pattison, David A, Gross, David J, Hicks, Rodney J

“…Abstract Purpose Treatment options for unresectable paraganglioma (PGL)/pheochromocytoma (PCC), especially with uncontrolled secondary hypertension (HTN), are…”
Get full text

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI by Arnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul, Ramsay, Stuart

“…Cardiac metastases from neuroendocrine neoplasms (NENs) are being detected with increasing frequency, although the optimal imaging strategy remains unclear. We…”
Get full text

The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT by Dudoignon, David, Pattison, David A, Legallois, Damien, Hicks, Rodney J, Aide, Nicolas

“…Positron Emission Tomography with Computed Tomography (PET/CT) is widely used in the assessment of many diseases, particularly including cancer. However, many…”
Get full text

Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review by McGeorge, Stephen, Kwok, Michael, Jiang, Andrew, Emmett, Louise, Pattison, David A., Thomas, Paul A., Yaxley, John W., Roberts, Matthew J.

“…PSMA PET is more accurate than conventional imaging (CT/bone scan) for staging of intermediate- or high-risk prostate cancer (PCa), but 5–10% of primary…”
Get full text

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging by Chikatamarla, Venkata Avinash, Okano, Satomi, Jenvey, Peter, Ansaldo, Alexander, Roberts, Matthew J., Ramsay, Stuart C., Thomas, Paul A., Pattison, David A.

“…Background Accurate prostate cancer imaging is critical for patient management. Multiple studies have demonstrated superior diagnostic accuracy of [ 68…”
Get full text

Intense focal pituitary FDG uptake due to intravascular large B‐cell lymphoma in pyrexia of unknown origin by Pattison, David A., Hofman, Michael S., Bazargan, Ali, Colman, Peter, Hicks, Rodney J.

Get full text

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT by Pattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy, Hicks, Rodney J.

“…Background Hyperglycaemia can influence 18 F-fluorodeoxyglucose (FDG) uptake due to competition for glucose transport and phosphorylation by hexokinase. Major…”
Get full text

Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies by Pattison, David A., MBBS, MPH, FRACP, Hofman, Michael S., MBBS, FRACP

“…This review provides practical guidance for clinicians involved in the management of endocrine malignancies, including endocrinologists, medical oncologists,…”
Get full text

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial by Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y, McJannett, Margaret M, Stockler, Martin R, Violet, John A, Williams, Scott G, Martin, Andrew J, Davis, Ian D, Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

“…Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with…”
Get full text

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study by Emmett, Louise, Buteau, James, Papa, Nathan, Moon, Daniel, Thompson, James, Roberts, Matthew J., Rasiah, Kris, Pattison, David A., Yaxley, John, Thomas, Paul, Hutton, Anthony C., Agrawal, Shikha, Amin, Amer, Blazevski, Alexandar, Chalasani, Venu, Ho, Bao, Nguyen, Andrew, Liu, Victor, Lee, Jonathan, Sheehan-Dare, Gemma, Kooner, Raji, Coughlin, Geoff, Chan, Lyn, Cusick, Thomas, Namdarian, Benjamin, Kapoor, Jada, Alghazo, Omar, Woo, Henry H., Lawrentschuk, Nathan, Murphy, Declan, Hofman, Michael S., Stricker, Phillip

“…Multiparametric magnetic resonance imaging (MRI) is validated for the detection of clinically significant prostate cancer (csPCa), although patients with…”
Get full text

Molecular imaging in the investigation of hypoglycaemic syndromes and their management by Pattison, David A, Hicks, Rodney J

“…There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and…”
Get full text

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial by Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

“…Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA)…”
Get full text

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation by Arnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L., Pattison, David A.

“…Purpose [ 18 F]PSMA-1007 offers advantages of low urinary tracer excretion and theoretical improved spatial resolution for imaging prostate cancer. However,…”
Get full text

Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI by Arnfield, Evyn, Pattison, David A.

“…A 69-year-old woman presented with symptomatic hypercalcemia and deranged liver function. 18F-FDG PET/CT showed intense confluent avidity throughout the…”
Get full text

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy by Hicks, Rodney J, Jackson, Price, Kong, Grace, Ware, Robert E, Hofman, Michael S, Pattison, David A, Akhurst, Timothy A, Drummond, Elizabeth, Roselt, Peter, Callahan, Jason, Price, Roger, Jeffery, Charmaine M, Hong, Emily, Noonan, Wayne, Herschtal, Alan, Hicks, Lauren J, Hedt, Amos, Harris, Matthew, Paterson, Brett M, Donnelly, Paul S

“…Imaging of somatostatin receptor expression is an established technique for staging of neuroendocrine neoplasia and determining the suitability of patients for…”
Get full text

Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer by Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C., Thomas, Paul A.

“…Introduction [ 18 F]PSMA-1007 has potential advantages over [ 68  Ga]Ga-PSMA-11, although limited prospective data evaluating diagnostic performance exist. The…”
Get full text

Lymph node classification in E-PSMA reporting guidelines for PSMA-PET by Arnfield, Evyn G., Roberts, Matthew J., Pattison, David A.

Get full text

(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity by Chang, Chian A, Pattison, David A, Tothill, Richard W, Kong, Grace, Akhurst, Tim J, Hicks, Rodney J, Hofman, Michael S

“…Pheochromocytomas (PCC) and paragangliomas (PGL) are neuroendocrine tumours arising from pluripotent neural crest stem cells and are associated with neurons of…”
Get full text

UpFrontPSMA: a randomized phase 2 study of sequential 177Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol) by Dhiantravan, Nattakorn, Emmett, Louise, Joshua, Anthony M., Pattison, David A., Francis, Roslyn J., Williams, Scott, Sandhu, Shahneen, Davis, Ian D., Vela, Ian, Neha, Nitika, Bressel, Mathias, Murphy, Declan G., Hofman, Michael S., Azad, Arun A.

“…Objective To assess the activity and safety of sequential lutetium‐177 (177Lu)‐PSMA‐617 and docetaxel vs docetaxel on a background of androgen deprivation…”
Get full text

18F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation by Pattison, David A, Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S, Hicks, Rodney J, Skandarajah, Anita

“…18F-FDG-avid thyroid incidentaloma (TI) is seen in approximately 2.5% of patients imaged for staging or response assessment of malignancy and represents…”
Get full text